Platelet-activating factor increases platelet-dependent glycoconjugate secretion from tracheal submucosal gland.
Using isolated glands from feline trachea, we examined the effect of platelet-activating factor (PAF) on radiolabeled glycoconjugate release and glandular contraction by measuring induced tension in the absence or presence of platelets. PAF alone did not produce any significant glandular contraction nor any significant change in glycoconjugate release from isolated glands. In the presence of purified platelets containing no plasma, PAF (10(-8) to 10(-5) M) produced significant glycoconjugate secretion in a dose-dependent fashion, but it produced no significant glandular contraction. PAF-evoked glycoconjugate secretion was time dependent, reaching a peak response of 277% of control 15-30 min after the exposure of isolated glands to 10(-5) M PAF in the presence of platelets and returning to 135% of controls at 2 h. Platelets alone did not produce any significant stimulation in glycoconjugate release. CV-3988, a known PAF antagonist, inhibited the secretory response to PAF. Methysergide, a known antagonist to receptors for 5-hydroxytryptamine, did not alter PAF-evoked glycoconjugate secretion. Both indomethacin and SQ 29,548, a thromboxane receptor antagonist, abolished the PAF-evoked glycoconjugate secretion from isolated submucosal glands. Epithiomethanothromboxane A2, a stable thromboxane A2 analogue, produced a significant increase in glycoconjugate secretion in a dose-dependent fashion. These findings indicate that PAF increases glycoconjugate release in the presence of platelets and that the increase is dependent on some aspect of platelet function, namely thromboxane generation.
Sasaki
T
T
First Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Shimura
S
S
Ikeda
K
K
Sasaki
H
H
Takishima
T
T
D000818:Animals; D001792:Blood Platelets / Q000502:physiology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002415:Cats; D005231:Fatty Acids, Unsaturated; D005944:Glucosamine / Q000378:metabolism; D006001:Glycoconjugates / Q000378:metabolism*; D006834:Hydrazines / Q000494:pharmacology; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D007700:Kinetics; D008784:Methysergide / Q000494:pharmacology; D009092:Mucous Membrane / Q000187:drug effects / Q000378:metabolism; D010742:Phospholipid Ethers / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D011865:Radioisotope Dilution Technique; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects / Q000378:metabolism*; D014316:Tritium
D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006001:Glycoconjugates; D006834:Hydrazines; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D014316:Tritium; D013928:Thromboxane A2; C037866:STA 2; C037913:CV 3988; C045749:SQ 29548; D005944:Glucosamine; D007213:Indomethacin; D008784:Methysergide